SUPN Healthcare

Supernus Pharmaceuticals, Inc.

$28.15-22.41%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 1.6B USD
Enterprise value: 1.3B USD
Full-time employees: 778

Overall health

Drawback: less profitable than most peersless profitable than peers
About average: growth, valuation and risk (debt, liquidity and share-price swings)growth, valuation and risk

Ranks #671 of 1,157 healthcare companies (bottom 43%)

See how it ranks against its peers

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.
Supernus Pharmaceuticals made a loss per share in its latest year after a profit the year before.
Operating margin at a 6-year low. -8.7% in 2025, the weakest of the last 6 years.
Supernus Pharmaceuticals's operating margin fell to -8.7% in 2025, its lowest in the 6 years of filings we have.
Valuation signals disagree. Cheaper than 76% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 76% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), Supernus Pharmaceuticals looks cheaper than 76% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Supernus Pharmaceuticals looks cheaper than 76% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 83% of peers, at an operating loss.
Revenue grew faster than 83% of peers, but the business runs at an operating loss (margin -16%).

StockQuotient Score

48/ 100▲ 2 since Oct 27 close

Oct 5 46 → Nov 4 48 (+2)

Valuation

Is the price right?

53/100

Moderate▲ 8 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 45 → 53

Share price -31.3%+4
Company's reported figures updated+1
Peer companies moved+3

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Mixed versus peers:

▲ EBITDA yield
▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-6.7%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield8.5%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 1.11Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield1.1%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield63.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

50/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 6.9%

Why

Mixed versus peers:

▲ Revenue growth
▲ 3-yr revenue
▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth9.4%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.42Sector median: 0.0584 · MAD: 0.0840

Revenue growth24.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 1.93Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

28/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 7.9 points to -15.7%

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-15.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-7.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.74Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-12.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.67Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin88.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-10.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Helped by:

▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.56

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.20Sector median: 0.6250 · MAD: 0.3380

Current ratio2.08×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.36Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.04×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.90Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Supernus Pharmaceuticals

Is Supernus Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 3, 2026) got weaker in some ways: operating margin fell 7.9 points to -15.7%. Its overall score is 48/100, up 2 since Oct 28, 2026.
How is Supernus Pharmaceuticals valued vs its peers?: Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers. EBITDA yield 8.5% vs a peer median of 4.0% (stronger than 76% of peers).EBITDA yield 8.5% vs peers 4.0% (stronger than 76% of peers). Earnings yield -6.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.7% vs peers 1.5% (weaker than 100% of peers).
Is Supernus Pharmaceuticals growing?: At about the same pace as its peers. Growth scores 50/100 against 1,393 healthcare peers. Revenue growth 24.9% vs a peer median of 6.1% (stronger than 83% of peers).Revenue growth 24.9% vs peers 6.1% (stronger than 83% of peers).
How profitable is Supernus Pharmaceuticals?: Less profitable than most of its peers. Profitability scores 28/100 against 1,393 healthcare peers. Operating margin -15.7% vs a peer median of 7.1% (weaker than 77% of peers).Operating margin -15.7% vs peers 7.1% (weaker than 77% of peers).
How risky is Supernus Pharmaceuticals?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 3, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 7.9 points to -15.7%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	776.8M USD	830.4M USD	+6.9%
Net income (12 months)	−29.1M USD	−109.9M USD	+278.2%
Operating margin	-7.8%	-15.7%	−7.9 pts
Free cash flow (12 months)	82.2M USD	18.8M USD	−77.2%
Cash	184.9M USD	180.0M USD	−2.7%
Shares outstanding	58.0M	58.1M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	86.9%	86.2%	88.2%	89.6%	▲ 1.4 pts
Operating margin	14.8%	6.9%	-0.9%	12.3%	-8.7%	▼ 21 pts
Net margin	9.2%	9.1%	0.2%	11.2%	-5.4%	▼ 17 pts
Return on assets (ROA)	3.2%	3.6%	0.1%	5.4%	-2.7%	▼ 8.1 pts
Return on equity (ROE)	6.5%	6.9%	0.1%	7.1%	-3.6%	▼ 11 pts
Free cash flow margin	—	17.4%	18.2%	25.9%	6.4%	▼ 19 pts
Current ratio	1.91×	1.07×	1.70×	2.35×	1.90×	▼ 19%
Quick ratio	1.63×	0.93×	1.43×	2.16×	1.57×	▼ 27%
Interest coverage	4.37×	6.52×	-2.18×	—	—	—

SUPN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Earnings slid into a loss. Loss per share this year after a profit last year.

Supernus Pharmaceuticals made a loss per share in its latest year after a profit the year before.

Operating margin at a 6-year low. -8.7% in 2025, the weakest of the last 6 years.

Supernus Pharmaceuticals's operating margin fell to -8.7% in 2025, its lowest in the 6 years of filings we have.

Valuation signals disagree. Cheaper than 76% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 76% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), Supernus Pharmaceuticals looks cheaper than 76% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, Supernus Pharmaceuticals looks cheaper than 76% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 83% of peers, at an operating loss.

Revenue grew faster than 83% of peers, but the business runs at an operating loss (margin -16%).

Questions investors ask about Supernus Pharmaceuticals

Is Supernus Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 3, 2026) got weaker in some ways: operating margin fell 7.9 points to -15.7%. Its overall score is 48/100, up 2 since Oct 28, 2026.

How is Supernus Pharmaceuticals valued vs its peers?

Priced about in line with its peers. Valuation scores 53/100 against 1,393 healthcare peers. EBITDA yield 8.5% vs a peer median of 4.0% (stronger than 76% of peers).EBITDA yield 8.5% vs peers 4.0% (stronger than 76% of peers). Earnings yield -6.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -6.7% vs peers 1.5% (weaker than 100% of peers).

Is Supernus Pharmaceuticals growing?

At about the same pace as its peers. Growth scores 50/100 against 1,393 healthcare peers. Revenue growth 24.9% vs a peer median of 6.1% (stronger than 83% of peers).Revenue growth 24.9% vs peers 6.1% (stronger than 83% of peers).

How profitable is Supernus Pharmaceuticals?

Less profitable than most of its peers. Profitability scores 28/100 against 1,393 healthcare peers. Operating margin -15.7% vs a peer median of 7.1% (weaker than 77% of peers).Operating margin -15.7% vs peers 7.1% (weaker than 77% of peers).

How risky is Supernus Pharmaceuticals?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

776.8M USD

830.4M USD

+6.9%

Net income (12 months)

−29.1M USD

−109.9M USD

+278.2%

Operating margin

-7.8%

-15.7%

−7.9 pts

Free cash flow (12 months)

82.2M USD

18.8M USD

−77.2%

Cash

184.9M USD

180.0M USD

−2.7%

Shares outstanding

58.0M

58.1M

+0.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

86.9%

86.2%

88.2%

89.6%

▲ 1.4 pts

Operating margin

14.8%

6.9%

-0.9%

12.3%

-8.7%

▼ 21 pts

Net margin

9.2%

9.1%

0.2%

11.2%

-5.4%

▼ 17 pts

Return on assets (ROA)

3.2%

3.6%

0.1%

5.4%

-2.7%

▼ 8.1 pts

Return on equity (ROE)

6.5%

6.9%

0.1%

7.1%

-3.6%

▼ 11 pts

Free cash flow margin

—

17.4%

18.2%

25.9%

6.4%

▼ 19 pts

Current ratio

1.91×

1.07×

1.70×

2.35×

1.90×

▼ 19%

Quick ratio

1.63×

0.93×

1.43×

2.16×

1.57×

▼ 27%

Interest coverage

4.37×

6.52×

-2.18×

—